Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Breast Cancer

Interventions

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

sargramostim

BIOLOGICAL

telomerase: 540-548 peptide vaccine

Trial Locations (1)

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00079157 - Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter